Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium selenate in mild to moderate Alzheimer's disease
ACTRN12611001200976Phase 2Recruiting
- Sponsor
- Velacor Therapeutics
- Start
- Nov 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sodium selenate in Alzheimer's disease (AD) (3 arms), sponsored by Velacor Therapeutics. Primary endpoint: Safety and tolerability. Started Nov 2011; status: recruiting.
02
Drugs
sodium selenate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12611001200976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001200976.